Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $63.25 Consensus PT from Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has been assigned an average rating of “Hold” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $61.60.

Several analysts have issued reports on SUPN shares. Zacks Research lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 8th. Piper Sandler upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $40.00 to $65.00 in a research note on Thursday, October 9th. TD Cowen raised their price objective on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Bank of America started coverage on Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They set a “buy” rating and a $65.00 price objective on the stock. Finally, Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th.

Insider Transactions at Supernus Pharmaceuticals

In other news, CEO Jack A. Khattar sold 59,900 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the sale, the chief executive officer directly owned 1,206,578 shares in the company, valued at approximately $61,016,649.46. The trade was a 4.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 710 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the sale, the vice president directly owned 14,508 shares in the company, valued at approximately $644,735.52. The trade was a 4.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 116,945 shares of company stock valued at $5,726,000 over the last ninety days. 8.80% of the stock is owned by insiders.

Institutional Trading of Supernus Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Armistice Capital LLC raised its stake in Supernus Pharmaceuticals by 7.4% during the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company’s stock worth $170,169,000 after acquiring an additional 360,000 shares in the last quarter. State Street Corp lifted its holdings in Supernus Pharmaceuticals by 2.9% during the 2nd quarter. State Street Corp now owns 2,208,560 shares of the specialty pharmaceutical company’s stock valued at $69,614,000 after purchasing an additional 63,210 shares during the last quarter. Geode Capital Management LLC boosted its position in Supernus Pharmaceuticals by 5.5% in the second quarter. Geode Capital Management LLC now owns 1,399,610 shares of the specialty pharmaceutical company’s stock valued at $44,121,000 after buying an additional 72,991 shares in the last quarter. Woodline Partners LP grew its stake in Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after buying an additional 490,835 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Supernus Pharmaceuticals by 67.1% during the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock worth $40,282,000 after buying an additional 338,584 shares during the last quarter.

Supernus Pharmaceuticals Stock Up 4.5%

NASDAQ:SUPN opened at $51.48 on Wednesday. The company’s 50 day moving average is $48.27 and its 200-day moving average is $42.37. Supernus Pharmaceuticals has a 12 month low of $29.16 and a 12 month high of $57.65. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -151.41, a P/E/G ratio of 0.60 and a beta of 0.71.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.82 by ($0.36). The firm had revenue of $170.00 million for the quarter, compared to the consensus estimate of $175.82 million. Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.Supernus Pharmaceuticals’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.69 earnings per share. Research analysts predict that Supernus Pharmaceuticals will post 2.38 EPS for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.